In Brief
This article was originally published in The Tan Sheet
Executive Summary
Senate backs pre-tax OTC purchases; infirst Healthcare lands $38M investment; Star Scientific faces fraud allegation; Vitamin Shoppe franchise opens in Panama.
You may also be interested in...
Infirst Later Than Expected With Lipid-Format Ibuprofen, But On Time In Business Plan
The London firm announces Unicough cough/cold product’s launch after reviewing clinical trial results, but holds off on a Flarin ibuprofen launch until completing a trial. “We’re very, very pleased with this, although originally we wanted to be there slightly earlier,” says CEO Manfred Scheske.
Infirst Later Than Expected With Lipid-Format Ibuprofen, But On Time In Business Plan
The London firm announces Unicough cough/cold product’s launch after reviewing clinical trial results, but holds off on a Flarin ibuprofen launch until completing a trial. “We’re very, very pleased with this, although originally we wanted to be there slightly earlier,” says CEO Manfred Scheske.
Glaxo Veteran Directs Infirst’s Jump Into Differentiated OTCs
U.K. biotech SEEK launches infirst HEALTHCARE to focus on commercializing consumer products, while the firm’s pipeline continues developing. Former GlaxoSmithKline exec Manfred Scheske leads infirst as it prepares cough remedy and analgesic launches in multiple markets.